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Abstract: Foot ulcers and their attendant complications are disquietingly high in people with 
diabetes, a majority of whom have underlying neuropathy. This review examines the evidence 
base underpinning the prevention and management of neuropathic diabetic foot ulcers in order 
to inform best clinical practice. Since it may be impractical to ask patients not to weight-bear 
at all, relief of pressure through the use of offloading casting devices remains the mainstay for 
management of neuropathic ulcers, whilst provision of appropriate footwear is essential in ulcer 
prevention. Simple non-surgical debridement and application of hydrogels are both effective 
in preparing the wound bed for healthy granulation and therefore enhancing healing. Initial 
empirical antibiotic therapy for infected ulcers should cover the most common bacterial flora. 
There is limited evidence supporting the use of adjunctive therapies such as hyperbaric oxygen 
and cytokines or growth factors. In selected cases, recombinant human platelet-derived growth 
factor has been shown to enhance healing; however, its widespread use cannot be advised due 
to the availability of more cost-effective approaches. While patient education may be beneficial, 
the evidence base remains thin and conflicting. In conclusion, best management of foot ulcers 
is achieved by what is taken out of the foot (pressure, callus, infection, and slough) rather than 
what is put on the foot (adjuvant treatment).
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Introduction
Definition
Diabetic foot ulcers (DFUs) are chronic ulceration (break in the continuity of the skin) 
occurring in the feet of people with diabetes. It has been estimated that one in every 
four patients with diabetes will develop a foot ulcer during their lifetime.1
Etiology
Foot ulceration in diabetes can either be associated with neuropathy (neuropathic ulcer), 
peripheral vascular disease (ischemic ulcer), or both (neuroischemic ulcer), although 
the final etiopathogenetic pathway may involve a combination of these primary risk 
factors and other causal factors such as trauma.2 However, up to 85% of DFUs are 
associated with neuropathy3 while between 10%–60% are associated with ischemia, 
depending on the studies considered.4 Neuropathic ulceration is usually orchestrated 
by foot deformity, high foot pressures, reduced soft tissue padding, and unattended 
or unnoticed trauma, entraining tissue damage. Once tissue breakdown occurs, the 
resultant ulceration becomes chronic as the insensate foot fails to convey nociceptive 
stimuli which are necessary to provoke protective behavior.
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Economics
In the US in 1999, the cost attributable to a new foot ulcer for 
a 40–65-year-old male was estimated at £19,000 in the 2 years 
after diagnosis,5 whilst in Sweden, the cost of healing a foot 
ulcer in 1997 was £11,000 without amputation and £21,000 
for a major amputation.6 More recently, in the Eurodiale study 
the total cost (direct and indirect) of treatment of a diabetic 
foot ulcer varied from £3500 for non-infected neuropathic 
ulcers to £13,000 for infected ischemic ulcers.7
Search sources
The following sources were used during this review: PubMed, 
Cochrane Library, NHS evidence, clinical evidence, OVID, 
EMBASE.
Level of evidence used
Meta-analysis, systematic reviews, randomized controlled 
trials (RCT), prospective studies.
Outcomes
Healing of diabetic foot ulcers. Prevention of new foot ulcers 
or re-ulceration.
Consumer summary
Foot ulcers are common in diabetics. One of the main causes 
of these ulcers is neuropathy (nerve damage),   making it 
difficult for the person to identify damage to their feet such 
as cuts, bruises, and pressure. We have researched various 
published studies to see which specific treatments are best 
indicated for DFUs. We found that casting (wrapping a hard 
fiberglass material such as plaster of Paris) can help enhance 
the healing of DFUs by reducing the amount of pressure on the 
wound, thus minimizing further tissue   breakdown. Also, 
the manual removal of dead tissue and slough (a procedure 
called debridement) by a foot   specialist such as a podiatrist 
can enhance wound healing. If the wound is infected, simple 
antibiotics can be prescribed to control infection. There is 
little evidence to support the use of other agents on the wound, 
some of which can be very expensive. Education of patients 
may reduce their chances of developing an ulcer, but this has 
to be done alongside other preventive measures.
Research questions
This review sought to critically appraise the available 
  evidence in order to answer the specific questions:
1.  What therapies/interventions are effective in speeding 
wound healing or increasing the proportion of healed 
diabetic foot ulcers?
2.  What interventions are effective in the prevention of 
diabetic foot ulcers?
The evidence
Therapies/interventions that enhance 
wound healing
Pressure relieving casts in the management of DFUs
We found one Cochrane review that concluded that total 
contact casting (TCC) is effective in healing ulcers.8 The 
trial of TCC only involved 40 people for 6 weeks and rates 
of infection and hospitalizations would need to be considered 
for longer term use. The same review concluded that there 
is no available evidence for the use of removable casts in 
the healing of foot ulcers. Similarly, we could not find any 
evidence to support the use of other forms of casting such 
as soft casts and scotchcast boots.
Debridement
A Cochrane review reported on the role of debridement 
on DFUs.9 Six RCTs of debridement were identified: four 
assessed hydrogels, with an additional study evaluating 
larval therapy against hydrogel, and one evaluated surgi-
cal debridement. Pooling the three RCTs which compared 
hydrogel with gauze or standard care suggested that hydrogels 
are significantly more effective in healing DFUs. Surgical 
debridement showed no significant benefit over standard 
debridement.10 One small trial, available only in abstract 
form, suggested that larvae resulted in a greater reduction in 
wound area compared with hydrogel, but 10 years on, the full 
trial results have yet to be published.11 A small prospective 
but non-randomized study of 13 subjects with methicillin-
resistant Staphylococcus aureus colonized DFUs reported 
that application of maggots eradicated methicillin-resistant 
S. aureus in 12 out of the 13 wounds.12 Other debridement 
methods such as enzyme preparations or polysaccharide 
beads have not been evaluated in DFUs.
Wound dressing
The enormous variety of types of wound dressing is not 
matched by robust evidence. A recent Cochrane review 
undertaken to compare silver-based wound dressings versus 
topical agents for treating DFUs concluded that no studies 
were found that were suitable for inclusion.
Role of vacuum-assisted closure (vAC) of wounds
Vacuum-assisted closure using negative topical pressure 
(125 mmHg) is a resurgent therapy in foot ulcer care.13–15 
Although VAC remains a relatively safe modality for   treatment 
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of diabetic foot wounds, two Cochrane reviews of studies 
  examining the use of VAC in diabetic foot wounds have 
concluded that the current evidence base is only supported 
by a limited number of under-powered, poorly-designed 
studies.16,17
Adjunctive therapies in the management  
of diabetic foot lesions
Platelet-derived growth factor (PDGF)
We found four multicenter RCTs assessing the role of 
  lyophilized recombinant human PDGF, beta-beta homodimer 
(rhPDGF-BB), purified from genetically engineered yeast in 
the treatment of chronic non-infected non-ischemic DFUs 
and one non-systematic review.18 All patients in the RCTs 
received standard care including adequate debridement. The 
first RCT was a Phase II company-led (Johnson and Johnson) 
trial19 whilst the others were Phase III trials.20 The prob-
ability of complete wound healing was significantly higher 
with rhPDGF-BB gel compared with placebo gel treatment. 
  Treatment with rhPDGF-BB gel also significantly decreased 
the time to complete healing by 30%. Adverse events and ulcer 
recurrence rates were similar in both treatment groups.
Granulocyte colony-stimulating factor (G-CSF)
Cruciani et al performed a meta-analysis to examine the role 
of G-CSF added to usual care on rates of infection, cure, and 
wound healing in people with diabetes who have a foot infec-
tion.21,22 They found that adding G-CSF did not significantly 
affect the likelihood of resolution of infection or wound heal-
ing, but was associated with reduced lower extremity surgical 
interventions, including   amputation.   Additionally, G-CSF 
reduced the duration of hospital stay, but did not affect the 
duration of systemic antibiotic therapy.
Honey
Although honey has been used since antiquity in the treat-
ment of chronic ulcers, there is a striking lack of data from 
carefully designed RCTs or prospective studies. One study 
suggested equivalence to polyvidone iodine in Wagner grade 
2 DFUs,23 but the design and statistical analysis of this study 
failed to use convincing methodologies.
Hyperbaric oxygen therapy (HBOT)
Two independent systematic reviews on HBOT concluded that 
systemic HBOT may reduce the incidence of major amputa-
tion in people with DFUs.24,25 However, most of the studies 
evaluated were relatively small. Therefore, further evidence 
is required from larger, more robust, and blinded studies. 
Nonetheless, systemic HBOT may be   considered in patients 
with ischemic ulcers and where revascularization is not pos-
sible. The benefit of topically administered HBOT has not 
been established.
Empirical antibiotics in the treatment  
of diabetic foot infections
We found no RCTs or systematic reviews that examined 
  different antimicrobial agents as empirical treatment for 
diabetic foot infections. However, one open-labeled random-
ized study compared the efficacy and safety of intravenous 
and oral formulations of linezolid to intravenous ampicillin-
sulbactam and intravenous and oral amoxicillin-clavulanate, 
based on the premise that aerobic Gram-positive cocci are 
the most frequent and virulent pathogens.26 In this study, 
overall clinical cure rates associated with linezolid and the 
comparator antibiotics were statistically equivalent.
Therapies/interventions that prevent  
new ulcers or recurrent ulceration
Therapeutic shoes in the prevention  
of DFUs in at-risk patients
A Cochrane review on the use of pressure relieving footwear 
in the prevention of DFUs concluded that whilst trials using 
customized insoles have shown some benefit, it is not pos-
sible to recommend any particular type of orthotic device 
(cushioning or pressure redistribution).8
Education and self-care practices
A Cochrane review of educational interventions in the pre-
vention of DFUs concluded that most of the RCTs included in 
the review were at high or unclear risk of bias. In some trials, 
foot care knowledge and self-reported patient   behavior seem 
to be positively influenced by education in the short term. 
The ultimate goal of educational interventions should be 
prevention of DFUs and amputation but only four RCTs 
reported these outcomes and only two reported sufficient data 
to examine this. There was insufficient robust evidence from 
these two studies that patient education alone is effective in 
achieving reductions in clinically relevant outcomes. Several 
studies to evaluate diabetic foot education also incorporate 
other standard prevention strategies such as education of pri-
mary care physicians and recommendations for consultations 
for high-risk patients for foot care and protective shoes.27,28
In fact, results of clinical studies report conflicting 
results. Malone et al conducted a prospective randomized 
clinical study to evaluate the influence of education on lower 
extremity amputations. During the follow-up period there 
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were significantly fewer ulcerations and amputations in the 
education arm.29 Litzelman et al also randomized 395 patients 
with diabetes assigned to either a multifaceted education and 
prevention program or usual care. Patients in the intervention 
group were less likely to have foot ulcers and more likely to 
report recommended self-care practices.27
In contrast, Lincoln et al found that education improved 
knowledge, but there was no difference in foot ulcers or 
amputations. They randomized 172 patients with newly 
healed DFUs to receive usual care or one-to-one education. 
At 12 months, the incidence of ulceration was the same in 
both groups (41%).30
Temperature self-assessment
There are three randomized clinical studies that compare stan-
dard prevention therapies consisting of therapeutic shoes and 
insoles, regular foot care by a podiatrist, and a standard foot-
specific education to temperature-monitoring intervention31 
(Table 1). In each of the studies, there was a significant reduction 
in the incidence of foot ulcerations in the temperature monitor-
ing group; patients in the standard therapy groups had a three- to 
ten-fold increased risk of developing an ulcer (Table 1).
Fat pad augmentation
Injectable silicone oil has been used for over 50 years. Pro-
spective studies have demonstrated that injectable silicone 
significantly increased tissue thickness on the sole of the foot 
and reduced peak foot pressures in high-risk diabetics compared 
to placebo-injected controls after 1 and 2 years.32,33 We found 
no prospective randomized studies that demonstrate a change 
in clinical outcomes such as ulceration or amputation using 
this approach.
Discussion
Potential pitfalls
•	 Failure to perform inspection on the bare foot (all shoes and 
socks removed). It is not uncommon for an infected toe ulcer 
to be missed because it was covered in a small dressing.
•	 Failure to assess for or recognize ischemia. It is rare to 
find a “purely neuropathic ulcer” and any evidence of 
ischemia must prompt urgent vascular assessment and/or 
referral.
Assessment
No specialist skills are required for a proper assessment of 
DFUs. A thorough history should be taken to elicit   neuropathy, 
peripheral vascular disease, renal status   (particular attention 
must be given to dialysis-treated subjects), foot care   behavior, 
foot wear, and any history of psychiatric illness such as 
anxiety and depression. Physical examination should include 
assessment for neuropathy using simple tools like the 10 g 
monofilament test or the neurothesiometer, or a composite 
test such as the neuropathic disability score (ankle reflex, 
vibrating tuning fork test, pinprick sensation, and hot/cold 
sensation). The foot is assessed for deformity, callus, and 
other pre-ulcerative lesions or foot ulcers. Footwear must also 
be assessed for suitability and whether therapeutic footwear 
is required. Ischemia is assessed by palpation of foot pulses 
and determination of ankle brachial index (the ratio of the 
systolic blood pressure at ankle to the systolic blood   pressure 
of the arm). The presence of gangrene, the absence of two or 
more foot pulses, or an ankle brachial pressure index ,0.9 
should prompt referral for non-invasive vascular tests and/or 
vascular surgery review to rule out clinically important 
  ischemia that can be considered for revascularization.
Treatment
The TCC remains effective for offloading neuropathic 
DFUs.34–36 The main issue with the TCC is that its applica-
tion and removal requires trained personnel and ulcers can 
sometimes develop within these casts when performed by 
unskilled persons. Other casting methods may be effective if 
patients are fully compliant and wear these at all times dur-
ing weight bearing.37 Where compliance is a major concern, 
these can be made irremovable by additionally wrapping a 
film of conventional cast.38
Table 1 Temperature studies to prevent re-ulceration
Author  Study population Study duration Study groups Ulceration Odds ratio  
(confidence interval)
Lavery39 Foot ulcer history 6 months 
n = 85
1. Standard therapy 
2. Temperature monitoring
2% 
20%
10.3 
(1.2–85.3)
Lavery40 Foot ulcer history 15 months 
n = 173
1. Standard therapy 
2. Structured examination 
3. Temperature monitoring
29.30% 
30.40% 
8.50%
4.4 (1.5–12.8) 
4.7 (1.6–13.9)
Armstrong31  Foot ulcer history  
orneuropathy and deformity
18 months 
n = 225
1. Standard therapy 
2. Temperature monitoring
12.20% 
4.70%
3.0 
(1.0–8.5)
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Debridement can be performed by a podiatrist as an 
  outpatient procedure but hydrocolloid gels are equally 
effective agents for debridement. Debridement involves 
the careful removal of dead or devitalized tissue and 
debris/slough, and preparing the wound bed for healthy 
granulation tissue to develop. Current evidence does not 
demonstrate superiority of surgical debridement over simple 
debridement.
For empirical therapy, antibiotics with activity predomi-
nantly against Gram-positive organisms (staphylococci and 
streptococci)26 or broad-spectrum antibiotics with increased 
activity against Gram-negative organisms and obligate anaer-
obes39 are effective. Amoxicillin-clavulanic acid at a dose of 
625 mg three times a day is an effective empirical antibiotic 
for infected DFUs.
Patient education remains an integral part of management 
of DFUs although this is based on “common sense” that has 
not been supported by clear evidence. Nonetheless, education 
for the prevention of DFUs has to be done in tandem with 
other preventative measures.
The recombinant growth factor rhPDGF-BB gel is 
licensed for use in the US. At a dose of 100 µg/g, it is effective 
in non-ischemic non-infected ulcers with an area ,10 cm2. It 
has a good side-effect profile but its use is likely to be limited 
by the associated high costs.
Granulocyte colony-stimulating factor may be considered 
in the treatment of infected DFUs, especially in patients with 
a limb-threatening infection, but it remains unclear which 
patients might benefit.
For necrotic, neuropathic sloughy ulcers, topical applica-
tion of sterile maggots can be used to speed debridement of 
ulcers and also to eradicate methicillin-resistant S. aureus. 
They can be either free range or applied in bags, but have 
to be changed every 3–4 days. They are contraindicated in 
ischemic or neuroischemic foot ulcers where they can cause 
side effects such as pain. Some patients can be psychologi-
cally averse to these “little organisms” and care must be taken 
to allay any fears or misconceptions.
Notwithstanding, one has to bear in mind that the absence 
of evidence does not mean evidence of ineffectiveness.
Specialist referral
•	 An orthotist or shoemaker must be available on-site 
to assess on and/or provide appropriate footwear to all 
patients with neuropathic foot ulcers.
•	 Patients needing casting devices for offloading should be 
sent via ambulance to the casting unit if this is not present 
on-site.
•	 A non-invasive vascular assessment should be requested 
and the vascular lab contacted to arrange early vascular 
studies in all patients with suspected ischemia. Patients 
who have confirmed lower limb ischemia or   present 
with ischemic gangrene should be considered for 
  revascularization. If this service is not available locally, 
arrangements should be made for patients to be trans-
ferred to the nearest vascular surgery service.
•	 In recalcitrant infections or limb-threatening infections, 
discuss with microbiology colleagues for advice on 
appropriate antimicrobials.
•	 A foot care program should be offered to patients on 
dialysis as DFUs are prevalent and can sometimes go 
undiagnosed.
•	 Some countries have specific recommendations. In the 
UK for instance, GPs are advised to refer all diabetic 
foot patients with an ulcer to a specialized diabetic foot 
service and to be seen by this team within 24 hours of 
presentation.
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